Arbutus Biopharma (ABUS) Tops Q1 EPS by 91c

Arbutus Biopharma (NASDAQ: ABUS) reported Q1 EPS of $0.87, $0.91 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $179.23 million versus the consensus estimate of $400 thousand.

For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.

You May Also Be Interested In

• Evolus (EOLS) Misses Q2 EPS by 8c; Offers Guidance
• Clover Health Investments (CLOV) Tops Q2 EPS by 1c; raises guidance
• Block, Inc. (XYZ) Tops Q2 EPS by 15c, Beats on Revenue; Offers Q3 Guidance